GMAB Genmab AS

Bolt Biotherapeutics ( NASDAQ:BOLT ) , a clinical-stage biotechnology company focused on next-generation cancer immunotherapies, posted second quarter 2025 results on August 14, 2025. The standout news was a significant improvement in GAAP earnings and operating loss, helped by cost reductions ...

Genmab A/S has published its Articles of Association dated August 12, 2025. The Articles of Association can be found on Genmab's website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com

Company Announcement ...

Epcoritamab combo reduced the risk of disease progression or death by 79% in the Phase 3 FL trial. Genmab raised its 2025 revenue outlook to $3.5-$3.7 billion after Q2 beat and 19% Y/Y growth. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off →

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

The mean of analysts' price targets for Genmab (GMAB) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.